{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:25:16Z","timestamp":1793157916105,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["314061271-TRR 205"],"award-info":[{"award-number":["314061271-TRR 205"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["314061271-TRR 205"],"award-info":[{"award-number":["314061271-TRR 205"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["314061271-TRR 205"],"award-info":[{"award-number":["314061271-TRR 205"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FA 466\/5-1"],"award-info":[{"award-number":["FA 466\/5-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DE 2657\/1-1"],"award-info":[{"award-number":["DE 2657\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009401","name":"Medizinischen Fakult\u00e4t, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"publisher","award":["Metiphys"],"award-info":[{"award-number":["Metiphys"]}],"id":[{"id":"10.13039\/501100009401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2012_A103"],"award-info":[{"award-number":["2012_A103"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2015_A228"],"award-info":[{"award-number":["2015_A228"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","award":["E-26\/211.294\/2021"],"award-info":[{"award-number":["E-26\/211.294\/2021"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Corticotroph macroadenomas are rare but difficult to manage intracranial neoplasms. Mutations in the two Cushing\u2019s disease mutational hotspots\n                    <jats:italic>USP8<\/jats:italic>\n                    and\n                    <jats:italic>USP48<\/jats:italic>\n                    are less frequent in corticotroph macroadenomas and invasive tumors. There is evidence that\n                    <jats:italic>TP53<\/jats:italic>\n                    mutations are not as rare as previously thought in these tumors. The aim of this study was to determine the prevalence of\n                    <jats:italic>TP53<\/jats:italic>\n                    mutations in corticotroph tumors, with emphasis on macroadenomas, and their possible association with clinical and tumor characteristics. To this end, the entire\n                    <jats:italic>TP53<\/jats:italic>\n                    coding region was sequenced in 86 functional corticotroph tumors (61\n                    <jats:italic>USP8<\/jats:italic>\n                    wild type; 66 macroadenomas) and the clinical characteristics of patients with\n                    <jats:italic>TP53<\/jats:italic>\n                    mutant tumors were compared with\n                    <jats:italic>TP53\/USP8<\/jats:italic>\n                    wild type and\n                    <jats:italic>USP8<\/jats:italic>\n                    mutant tumors. We found pathogenic\n                    <jats:italic>TP53<\/jats:italic>\n                    variants in 9 corticotroph tumors (all macroadenomas and\n                    <jats:italic>USP8<\/jats:italic>\n                    wild type).\n                    <jats:italic>TP53<\/jats:italic>\n                    mutant tumors represented 14% of all functional corticotroph macroadenomas and 24% of all invasive tumors, were significantly larger and invasive, and had higher Ki67 indices and Knosp grades compared to wild type tumors. Patients with\n                    <jats:italic>TP53<\/jats:italic>\n                    mutant tumors had undergone more therapeutic interventions, including radiation and bilateral adrenalectomy. In conclusion, pathogenic\n                    <jats:italic>TP53<\/jats:italic>\n                    variants are more frequent than expected, representing a relevant amount of functional corticotroph macroadenomas and invasive tumors.\n                    <jats:italic>TP53<\/jats:italic>\n                    mutations associated with more aggressive tumor features and difficult to manage disease.\n                  <\/jats:p>","DOI":"10.1186\/s40478-022-01437-1","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T07:03:12Z","timestamp":1663570992000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["TP53 mutations in functional corticotroph tumors are linked to invasion and worse clinical outcome"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2555-0602","authenticated-orcid":false,"given":"Luis Gustavo","family":"Perez-Rivas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Albani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sicheng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun","family":"Roeber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Assi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Deutschbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Fassnacht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica R.","family":"Gadelha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad R.","family":"Hermus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter K.","family":"Stalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Tichomirowa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Rotermund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Flitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Buchfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Nasi-Kordhishti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Honegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Thorsteinsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Saeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Herms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Reincke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marily","family":"Theodoropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,19]]},"reference":[{"key":"1437_CR1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noy131","volume":"20","author":"QT Ostrom","year":"2018","unstructured":"Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS (2018) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011\u20132015. Neuro Oncol 20:iv1-86","journal-title":"Neuro Oncol"},{"key":"1437_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1530\/EJE-17-0933","volume":"178","author":"A McCormack","year":"2018","unstructured":"McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G et al (2018) Treatment of aggressive pituitary tumours and carcinomas: results of a European society of endocrinology (ESE) survey 2016. Eur J Endocrinol 178:265\u2013276","journal-title":"Eur J Endocrinol"},{"key":"1437_CR3","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR et al (2021) Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol 9:847\u2013875","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1437_CR4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1530\/EJE-13-0634","volume":"170","author":"C Dimopoulou","year":"2013","unstructured":"Dimopoulou C, Schopohl J, Rachinger W, Buchfelder M, Honegger J, Reincke M et al (2013) Long-term remission and recurrence rates after first and second transsphenoidal surgery for Cushing\u2019s disease: care reality in the Munich metropolitan region. Eur J Endocrinol 170:283\u2013292","journal-title":"Eur J Endocrinol"},{"key":"1437_CR5","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-20-1088","volume":"184","author":"M Reincke","year":"2021","unstructured":"Reincke M, Albani A, Assie G, Bancos I, Brue T, Buchfelder M et al (2021) Corticotroph tumor progression after bilateral adrenalectomy (Nelson\u2019s syndrome): systematic review and expert consensus recommendations. Eur J Endocrinol 184:P1-16","journal-title":"Eur J Endocrinol"},{"key":"1437_CR6","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1210\/clinem\/dgz200","volume":"105","author":"A Fountas","year":"2020","unstructured":"Fountas A, Lim ES, Drake WM, Powlson AS, Gurnell M, Martin NM et al (2020) Outcomes of patients with Nelson\u2019s syndrome after primary treatment: a multicenter study from 13 UK pituitary centers. J Clin Endocrinol Metab 105:1527\u20131537","journal-title":"J Clin Endocrinol Metab"},{"key":"1437_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/BF03345482","volume":"22","author":"SA Kemink","year":"1999","unstructured":"Kemink SA, Wesseling P, Pieters GF, Verhofstad AA, Hermus AR, Smals AG (1999) Progression of a Nelson\u2019s adenoma to pituitary carcinoma; a case report and review of the literature. J Endocrinol Invest 22:70\u201375","journal-title":"J Endocrinol Invest"},{"key":"1437_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/ng.3166","volume":"47","author":"M Reincke","year":"2015","unstructured":"Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, Beuschlein F et al (2015) Mutations in the deubiquitinase gene USP8 cause Cushing\u2019s disease. Nat Genet 47:31\u201338","journal-title":"Nat Genet"},{"key":"1437_CR9","doi-asserted-by":"publisher","first-page":"E997","DOI":"10.1210\/jc.2015-1453","volume":"100","author":"LG P\u00e9rez-Rivas","year":"2015","unstructured":"P\u00e9rez-Rivas LG, Theodoropoulou M, Ferra\u00f9 F, Nusser C, Kawaguchi K, Stratakis CA et al (2015) The Gene of the ubiquitin-specific protease 8 is frequently mutated in adenomas causing Cushing\u2019s disease. J Clin Endocrinol Metab 100:E997-1004","journal-title":"J Clin Endocrinol Metab"},{"key":"1437_CR10","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/cr.2015.20","volume":"25","author":"Z-Y Ma","year":"2015","unstructured":"Ma Z-Y, Song Z-J, Chen J-H, Wang Y-F, Li S-Q, Zhou L-F et al (2015) Recurrent gain-of-function USP8 mutations in Cushing\u2019s disease. Cell Res 25:306\u2013317","journal-title":"Cell Res"},{"key":"1437_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1530\/EJE-15-0689","volume":"174","author":"K Hayashi","year":"2016","unstructured":"Hayashi K, Inoshita N, Kawaguchi K, Ardisasmita AI, Suzuki H, Fukuhara N et al (2016) The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing\u2019s disease. Eur J Endocrinol 174:213\u2013226","journal-title":"Eur J Endocrinol"},{"key":"1437_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1530\/EJE-17-0634","volume":"178","author":"LG P\u00e9rez-Rivas","year":"2018","unstructured":"P\u00e9rez-Rivas LG, Theodoropoulou M, Puar TH, Fazel J, Stieg MR, Ferra\u00f9 F et al (2018) Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelson\u2019s tumor. Eur J Endocrinol 178:59\u201365","journal-title":"Eur J Endocrinol"},{"key":"1437_CR13","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/cen.13802","volume":"89","author":"A Albani","year":"2018","unstructured":"Albani A, P\u00e9rez-Rivas LG, Dimopoulou C, Zopp S, Col\u00f3n-Bolea P, Roeber S et al (2018) The USP8 mutational status may predict long-term remission in patients with Cushing\u2019s disease. Clin Endocrinol (Oxf) 89:454\u2013458","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1437_CR14","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1158\/1078-0432.CCR-16-0790","volume":"23","author":"WL Bi","year":"2017","unstructured":"Bi WL, Horowitz P, Greenwald NF, Abedalthagafi M, Agarwalla PK, Gibson WJ et al (2017) Landscape of genomic alterations in pituitary adenomas. Clin Cancer Res 23:1841\u20131851","journal-title":"Clin Cancer Res"},{"key":"1437_CR15","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1038\/cr.2016.114","volume":"26","author":"Z-J Song","year":"2016","unstructured":"Song Z-J, Reitman ZJ, Ma Z-Y, Chen J-H, Zhang Q-L, Shou X-F et al (2016) The genome-wide mutational landscape of pituitary adenomas. Cell Res 26:1255\u20131259","journal-title":"Cell Res"},{"key":"1437_CR16","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1038\/s41467-018-05275-5","volume":"9","author":"J Chen","year":"2018","unstructured":"Chen J, Jian X, Deng S, Ma Z, Shou X, Shen Y et al (2018) Identification of recurrent USP48 and BRAF mutations in Cushing\u2019s disease. Nat Commun 9:3171","journal-title":"Nat Commun"},{"key":"1437_CR17","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1093\/neuonc\/noz109","volume":"21","author":"S Sbiera","year":"2019","unstructured":"Sbiera S, Perez-Rivas LG, Taranets L, Weigand I, Flitsch J, Graf E et al (2019) Driver mutations in USP8 wild-type Cushing\u2019s disease. Neuro Oncol 21:1273\u20131283","journal-title":"Neuro Oncol"},{"key":"1437_CR18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ccell.2019.11.002","volume":"37","author":"M Neou","year":"2020","unstructured":"Neou M, Villa C, Armignacco R, Jouinot A, Raffin-Sanson ML, Septier A et al (2020) Pangenomic classification of pituitary neuroendocrine tumors. Cancer Cell 37:123-134.e5","journal-title":"Cancer Cell"},{"key":"1437_CR19","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1210\/clinem\/dgaa853","volume":"106","author":"AV Uzilov","year":"2021","unstructured":"Uzilov AV, Taik P, Cheesman KC, Javanmard P, Ying K, Roehnelt A et al (2021) USP8 and TP53 drivers are associated with CNV in a corticotroph adenoma cohort enriched for aggressive tumors. J Clin Endocrinol Metab 106:826\u2013842","journal-title":"J Clin Endocrinol Metab"},{"key":"1437_CR20","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1210\/clinem\/dgaa749","volume":"106","author":"O Casar-Borota","year":"2021","unstructured":"Casar-Borota O, Boldt HB, Engstr\u00f6m BE, Andersen MS, Baussart B, Bengtsson D et al (2021) Corticotroph aggressive pituitary tumors and carcinomas frequently harbor ATRX mutations. J Clin Endocrinol Metab 106:1183\u20131194","journal-title":"J Clin Endocrinol Metab"},{"key":"1437_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","volume":"578","author":"PJ Campbell","year":"2020","unstructured":"Campbell PJ, Getz G, Korbel JO, Stuart JM, Jennings JL, Stein LD et al (2020) Pan-cancer analysis of whole genomes. Nature 578:82\u201393","journal-title":"Nature"},{"key":"1437_CR22","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/humu.23035","volume":"37","author":"L Bouaoun","year":"2016","unstructured":"Bouaoun L, Sonkin D, Ardin M, Hollstein M, Byrnes G, Zavadil J et al (2016) TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum Mutat 37:865\u2013876","journal-title":"Hum Mutat"},{"key":"1437_CR23","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/neuonc\/noz119","volume":"21","author":"C Horbinski","year":"2019","unstructured":"Horbinski C, Ligon KL, Brastianos P, Huse JT, Venere M, Chang S et al (2019) The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro Oncol 21:1498\u20131508","journal-title":"Neuro Oncol"},{"key":"1437_CR24","doi-asserted-by":"publisher","first-page":"4612","DOI":"10.1038\/s41467-021-24812-3","volume":"12","author":"J van Riet","year":"2021","unstructured":"van Riet J, van de Werken HJG, Cuppen E, Eskens FALM, Tesselaar M, van Veenendaal LM et al (2021) The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets. Nat Commun 12:4612","journal-title":"Nat Commun"},{"key":"1437_CR25","first-page":"50","volume":"77","author":"V Herman","year":"1993","unstructured":"Herman V, Drazin NZ, Gonsky R, Melmed S (1993) Molecular screening of pituitary adenomas for gene mutations and rearrangements. J Clin Endocrinol Metab 77:50\u201355","journal-title":"J Clin Endocrinol Metab"},{"key":"1437_CR26","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/j.1365-2265.1994.tb02797.x","volume":"41","author":"A Levy","year":"1994","unstructured":"Levy A, Hall L, Yeudall WA, Lightman SL (1994) p53 gene mutations in pituitary adenomas: rare events. Clin Endocrinol (Oxf) 41:809\u2013814","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1437_CR27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12022-007-9006-y","volume":"18","author":"Y Tanizaki","year":"2007","unstructured":"Tanizaki Y, Jin L, Scheithauer BW, Kovacs K, Roncaroli F, Lloyd RV (2007) P53 gene mutations in pituitary carcinomas. Endocr Pathol 18:217\u2013222","journal-title":"Endocr Pathol"},{"key":"1437_CR28","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/j.1365-2265.2008.03404.x","volume":"2009","author":"ST Kawashima","year":"2009","unstructured":"Kawashima ST, Usui T, Sano T, Iogawa H, Hagiwara H, Tamanaha T et al (2009) P53 gene mutation in an atypical corticotroph adenoma with Cushing\u2019s disease. Clin Endocrinol (Oxf) 2009:656\u2013657","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1437_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00401-013-1084-y","volume":"126","author":"J Trouillas","year":"2013","unstructured":"Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G et al (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126:123\u2013135","journal-title":"Acta Neuropathol"},{"key":"1437_CR30","unstructured":"Phan J, Jin Y, Zhang H, Qiang W, Shekhtman E, Shao D et al (2020) ALFA: allele frequency aggregator: national center for biotechnology information, U.S. National Library of Medicine. Available from www.ncbi.nlm.nih.gov\/snp\/docs\/gsr\/alfa\/"},{"key":"1437_CR31","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","volume":"581","author":"KJ Karczewski","year":"2020","unstructured":"Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alf\u00f6ldi J, Wang Q et al (2020) The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581:434\u2013443","journal-title":"Nature"},{"key":"1437_CR32","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gkz836","volume":"48","author":"S Fairley","year":"2020","unstructured":"Fairley S, Lowy-Gallego E, Perry E, Flicek P (2020) The International genome sample resource (IGSR) collection of open human genomic variation resources. Nucleic Acids Res 48:D941\u2013D947","journal-title":"Nucleic Acids Res"},{"key":"1437_CR33","doi-asserted-by":"publisher","first-page":"8424","DOI":"10.1073\/pnas.1431692100","volume":"100","author":"S Kato","year":"2003","unstructured":"Kato S, Han S-Y, Liu W, Otsuka K, Shibata H, Kanamaru R et al (2003) Understanding the function\u2013structure and function\u2013mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci 100:8424\u20138429","journal-title":"Proc Natl Acad Sci"},{"key":"1437_CR34","doi-asserted-by":"publisher","first-page":"6976","DOI":"10.1038\/sj.onc.1208839","volume":"24","author":"T Kawaguchi","year":"2005","unstructured":"Kawaguchi T, Kato S, Otsuka K, Watanabe G, Kumabe T, Tominaga T et al (2005) The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library. Oncogene 24:6976\u20136981","journal-title":"Oncogene"},{"key":"1437_CR35","first-page":"4092","volume":"61","author":"MS Greenblatt","year":"2001","unstructured":"Greenblatt MS, Chappuis PO, Bond JP, Hamel N, Foulkes WD (2001) TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res 61:4092\u20134097","journal-title":"Cancer Res"},{"key":"1437_CR36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000500688","volume":"110","author":"A Sesta","year":"2020","unstructured":"Sesta A, Cassarino MF, Terreni M, Ambrogio AG, Libera L, Bardelli D et al (2020) Ubiquitin-Specific Protease 8 mutant corticotrope adenomas present unique secretory and molecular features and shed light on the role of ubiquitylation on ACTH processing. Neuroendocrinology 110:119\u2013129","journal-title":"Neuroendocrinology"},{"key":"1437_CR37","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0796","volume":"178","author":"G Raverot","year":"2018","unstructured":"Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V et al (2018) European society of endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178:G1-24","journal-title":"Eur J Endocrinol"},{"key":"1437_CR38","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1227\/00006123-199604000-00027","volume":"38","author":"K Thapar","year":"1996","unstructured":"Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER (1996) p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38:765\u201370","journal-title":"Neurosurgery"},{"key":"1437_CR39","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1093\/carcin\/bgi356","volume":"27","author":"N Gonin-Laurent","year":"2006","unstructured":"Gonin-Laurent N, Gibaud A, Huygue M, Lef\u00e8vre SH, Le Bras M, Chauveinc L et al (2006) Specific TP53 mutation pattern in radiation-induced sarcomas. Carcinogenesis 27:1266\u20131272","journal-title":"Carcinogenesis"},{"key":"1437_CR40","first-page":"1","volume":"3","author":"JP Whitehouse","year":"2021","unstructured":"Whitehouse JP, Howlett M, Federico A, Kool M, Endersby R, Gottardo NG (2021) Defining the molecular features of radiation-induced glioma: a systematic review and meta-analysis. Neuro-Oncol Adv 3:1\u201316","journal-title":"Neuro-Oncol Adv"},{"key":"1437_CR41","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s11102-009-0194-y","volume":"14","author":"EM Pinto","year":"2011","unstructured":"Pinto EM, Siqueira SACC, Cukier P, Fragoso MCBVCBV, Lin CJ, De Mendonca BB et al (2011) Possible role of a radiation-induced p53 mutation in a Nelson\u2019s syndrome patient with a fatal outcome. Pituitary 14:400\u2013404","journal-title":"Pituitary"},{"key":"1437_CR42","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00401-019-02055-3","volume":"139","author":"BA Orr","year":"2020","unstructured":"Orr BA, Clay MR, Pinto EM, Kesserwan C (2020) An update on the central nervous system manifestations of Li\u2013Fraumeni syndrome. Acta Neuropathol 139:669\u201387","journal-title":"Acta Neuropathol"},{"key":"1437_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-022-05478-8","author":"H Birk","year":"2020","unstructured":"Birk H, Kandregula S, Cuevas-Ocampo A, Wang CJ, Kosty J, Notarianni C (2022) Pediatric pituitary adenoma and medulloblastoma in the setting of p53 mutation: case report and review of the literature. Childs Nerv Syst. https:\/\/doi.org\/10.1007\/s00381-022-05478-8","journal-title":"Childs Nerv Syst"},{"key":"1437_CR44","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.canlet.2004.01.016","volume":"210","author":"F Granja","year":"2004","unstructured":"Granja F, Morari J, Morari EC, Correa LAC, Assump\u00e7\u00e3o LVM, Ward LS (2004) Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. Cancer Lett 210:151\u2013157","journal-title":"Cancer Lett"},{"key":"1437_CR45","doi-asserted-by":"publisher","first-page":"e492","DOI":"10.1038\/cddis.2013.24","volume":"4","author":"C Sagne","year":"2013","unstructured":"Sagne C, Marcel V, Amadou A, Hainaut P, Olivier M, Hall J (2013) A meta-analysis of cancer risk associated with the TP53 intron 3 duplication polymorphism (rs17878362): geographic and tumor-specific effects. Cell Death Dis 4:e492","journal-title":"Cell Death Dis"},{"key":"1437_CR46","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1158\/1078-0432.CCR-08-1719","volume":"15","author":"VR Katkoori","year":"2009","unstructured":"Katkoori VR, Jia X, Shanmugam C, Wan W, Meleth S, Bumpers H et al (2009) Prognostic significance of p53 Codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin Cancer Res 15:2406\u20132416","journal-title":"Clin Cancer Res"},{"key":"1437_CR47","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/ng1093","volume":"33","author":"P Dumont","year":"2003","unstructured":"Dumont P, Leu JIJ, Della Pietra AC, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357\u2013365","journal-title":"Nat Genet"},{"key":"1437_CR48","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1101\/gad.309062.117","volume":"32","author":"S Basu","year":"2018","unstructured":"Basu S, Gnanapradeepan K, Barnoud T, Kung CP, Tavecchio M, Scott J et al (2018) Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1\u03b1. Genes Dev 32:230\u2013243","journal-title":"Genes Dev"},{"key":"1437_CR49","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.mce.2017.02.017","volume":"446","author":"G Yagnik","year":"2017","unstructured":"Yagnik G, Jahangiri A, Chen R, Wagner JR, Aghi MK (2017) Role of a p53 polymorphism in the development of nonfunctional pituitary adenomas. Mol Cell Endocrinol 446:81\u201390","journal-title":"Mol Cell Endocrinol"},{"key":"1437_CR50","doi-asserted-by":"publisher","first-page":"4861","DOI":"10.3390\/ijms23094861","volume":"23","author":"S Andonegui-Elguera","year":"2022","unstructured":"Andonegui-Elguera S, Silva-Rom\u00e1n G, Pe\u00f1a-Mart\u00ednez E, Taniguchi-Ponciano K, Vela-Pati\u00f1o S, Remba-Shapiro I et al (2022) The genomic landscape of corticotroph tumors: from silent adenomas to ACTH-secreting carcinomas. Int J Mol Sci. 23:4861","journal-title":"Int J Mol Sci."}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-022-01437-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-022-01437-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-022-01437-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T08:17:25Z","timestamp":1663575445000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-022-01437-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,19]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1437"],"URL":"https:\/\/doi.org\/10.1186\/s40478-022-01437-1","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,19]]},"assertion":[{"value":"4 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the Declaration of Helsinki and was approved by the ethics committee of the LMU Munich (Nr. 643-16). All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"139"}}